Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Background Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine
kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge …
kinase (KIT), and platelet-derived growth factor receptor α (PDGFRA) is a clinical challenge …
Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial
MF Mulcahy, A Mahvash, M Pracht… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To study the impact of transarterial Yttrium-90 radioembolization (TARE) in
combination with second-line systemic chemotherapy for colorectal liver metastases (CLM) …
combination with second-line systemic chemotherapy for colorectal liver metastases (CLM) …
Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review
A Dimitrakopoulou-Strauss, U Ronellenfitsch… - Clinical and translational …, 2017 - Springer
Purpose Improvement of the therapeutic approaches in gastrointestinal stromal tumors
(GIST) by the introduction of targeted therapies requires appropriate diagnostic tools, which …
(GIST) by the introduction of targeted therapies requires appropriate diagnostic tools, which …
Current management of gastrointestinal stromal tumors: surgery, current biomarkers, mutations, and therapy
In the past decade, the addition of molecular diagnosis of mutations and use of tyrosine
kinase inhibitors (TKIs), either as neoadjuvant/adjuvant therapy with surgery or as primary …
kinase inhibitors (TKIs), either as neoadjuvant/adjuvant therapy with surgery or as primary …
Radiomics nomogram for predicting the malignant potential of gastrointestinal stromal tumours preoperatively
Objective To develop and evaluate a radiomics nomogram for differentiating the malignant
risk of gastrointestinal stromal tumours (GISTs). Methods A total of 222 patients (primary …
risk of gastrointestinal stromal tumours (GISTs). Methods A total of 222 patients (primary …
[HTML][HTML] Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging …
J Kalkmann, M Zeile, G Antoch, F Berger… - Cancer …, 2012 - ncbi.nlm.nih.gov
The aim was to reach consensus in imaging for staging and follow-up as well as for therapy
response assessment in patients with gastrointestinal stromal tumours (GIST). The German …
response assessment in patients with gastrointestinal stromal tumours (GIST). The German …
[HTML][HTML] A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma
PH Goncalves, LK Heilbrun, MT Barrett, S Kummar… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Purpose Vorinostat is a histone deacetylase inhibitor (HDACi). Based on a confirmed partial
response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior …
response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior …
The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure-one institution study
P Rutkowski, E Bylina, A Klimczak, T Świtaj… - BMC cancer, 2012 - Springer
Background Gastrointestinal stromal tumors (GIST) mutational status is recognized factor
related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib …
related to the results of tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib …
CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive imaging biomarker of clinical benefit than …
M Meyer, P Hohenberger, P Apfaltrer, T Henzler… - European journal of …, 2013 - Elsevier
OBJECTIVES: Dual-energy CT (DECT) allows quantification of intravenously injected
iodinated contrast media in tumors, and therefore may be considered as a surrogate marker …
iodinated contrast media in tumors, and therefore may be considered as a surrogate marker …
Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors as a fourth-or later-line therapy: a multicenter, single-arm, open-label …
J Li, S Cai, Y Zhou, J Zhang, Y Zhou, H Cao, X Wu… - Clinical Cancer …, 2022 - AACR
Purpose: This is a phase II multicenter, single-arm, open-label study assessing the efficacy,
safety, and pharmacokinetics (PK) of ripretinib in Chinese patients with advanced …
safety, and pharmacokinetics (PK) of ripretinib in Chinese patients with advanced …